JPWO2020257489A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020257489A5 JPWO2020257489A5 JP2021573441A JP2021573441A JPWO2020257489A5 JP WO2020257489 A5 JPWO2020257489 A5 JP WO2020257489A5 JP 2021573441 A JP2021573441 A JP 2021573441A JP 2021573441 A JP2021573441 A JP 2021573441A JP WO2020257489 A5 JPWO2020257489 A5 JP WO2020257489A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antisense oligomer
- pharmaceutically acceptable
- acceptable salt
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025113283A JP2025174961A (ja) | 2019-06-19 | 2025-07-03 | 筋ジストロフィーを治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863456P | 2019-06-19 | 2019-06-19 | |
| US62/863,456 | 2019-06-19 | ||
| PCT/US2020/038483 WO2020257489A1 (en) | 2019-06-19 | 2020-06-18 | Methods for treating muscular dystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113283A Division JP2025174961A (ja) | 2019-06-19 | 2025-07-03 | 筋ジストロフィーを治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536495A JP2022536495A (ja) | 2022-08-17 |
| JP2022536495A5 JP2022536495A5 (https=) | 2023-06-19 |
| JPWO2020257489A5 true JPWO2020257489A5 (https=) | 2023-06-19 |
Family
ID=74040497
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573441A Withdrawn JP2022536495A (ja) | 2019-06-19 | 2020-06-18 | 筋ジストロフィーを治療する方法 |
| JP2025113283A Pending JP2025174961A (ja) | 2019-06-19 | 2025-07-03 | 筋ジストロフィーを治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025113283A Pending JP2025174961A (ja) | 2019-06-19 | 2025-07-03 | 筋ジストロフィーを治療する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220296633A1 (https=) |
| EP (1) | EP3987029A1 (https=) |
| JP (2) | JP2022536495A (https=) |
| WO (1) | WO2020257489A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200131231A1 (en) | 2017-02-17 | 2020-04-30 | Oxford University Innovation Limited | Cell penetrating peptides |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| CN113453723A (zh) | 2018-12-07 | 2021-09-28 | 牛津大学科技创新有限公司 | 接头 |
| CA3211038A1 (en) * | 2021-02-12 | 2022-08-18 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| JP3022967B2 (ja) | 1985-03-15 | 2000-03-21 | アンチバイラルズ インコーポレイテッド | 立体規則性ポリヌクレオチド結合ポリマー |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| WO1994002595A1 (en) | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| WO1999042091A2 (en) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
| US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
| US7163695B2 (en) | 1999-12-29 | 2007-01-16 | Mixson A James | Histidine copolymer and methods for using same |
| DK2735568T3 (da) | 2006-05-10 | 2017-11-13 | Sarepta Therapeutics Inc | Oligonukleotidanaloger med kationiske bindinger mellem underenheder |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| CA2906812A1 (en) * | 2013-03-15 | 2014-09-18 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
| SI3554554T1 (sl) * | 2016-12-19 | 2023-02-28 | Sarepta Therapeutics, Inc. | Oligomerni konjugati, ki preskakujejo ekson za mišično distrofijo |
| IL297528A (en) * | 2016-12-19 | 2022-12-01 | Sarepta Therapeutics Inc | Exon-skipping oligomer conjugates for muscular dystrophy |
| SMT202200366T1 (it) * | 2016-12-19 | 2022-11-18 | Sarepta Therapeutics Inc | Coniugati di oligomeri per salto di esone per distrofia muscolare |
| MX2019008199A (es) * | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| AR112538A1 (es) * | 2017-08-31 | 2019-11-06 | Sarepta Therapeutics Inc | Métodos para el tratamiento de distrofia muscular |
| EA201991450A1 (ru) * | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| WO2019079637A2 (en) * | 2017-10-18 | 2019-04-25 | Sarepta Therapeutics, Inc. | ANTISENSE OLIGOMERIC COMPOUNDS |
| EP3955966A1 (en) * | 2019-04-18 | 2022-02-23 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
-
2020
- 2020-06-18 EP EP20735838.3A patent/EP3987029A1/en active Pending
- 2020-06-18 WO PCT/US2020/038483 patent/WO2020257489A1/en not_active Ceased
- 2020-06-18 US US17/618,100 patent/US20220296633A1/en not_active Abandoned
- 2020-06-18 JP JP2021573441A patent/JP2022536495A/ja not_active Withdrawn
-
2025
- 2025-07-03 JP JP2025113283A patent/JP2025174961A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530560A5 (https=) | ||
| JP7792371B2 (ja) | ＧａｌＮＡｃ誘導体 | |
| JPWO2020257489A5 (https=) | ||
| JP2023078293A5 (https=) | ||
| JP7478210B2 (ja) | 修飾オリゴヌクレオチド及び使用方法 | |
| JP2020511943A5 (https=) | ||
| US9738678B2 (en) | Substituted nucleoside derivatives with antiviral and antimicrobial properties | |
| JP2020040972A (ja) | テノホビルアラフェナミドヘミフマレート | |
| JP2020503009A5 (https=) | ||
| JP2021526017A5 (https=) | ||
| JP2019525918A5 (https=) | ||
| JP2019062913A5 (https=) | ||
| JP2004525142A5 (https=) | ||
| JP5841938B2 (ja) | 治療効能のある変形核酸及びグアノシンを含有するオリゴヌクレオチド変形体 | |
| JP2018525030A5 (https=) | ||
| JP2018530325A5 (https=) | ||
| JP2021500016A5 (https=) | ||
| JP2021090458A5 (https=) | ||
| JP2019527549A5 (https=) | ||
| JP2022180420A5 (https=) | ||
| ES2488821T3 (es) | Proceso de preparación de un compuesto antiviral | |
| JP2021510512A5 (https=) | ||
| JP2020521491A5 (https=) | ||
| US20200190516A1 (en) | Exon skipping oligomer conjugates for muscular dystropy | |
| JP2018518167A5 (https=) |